Hcw Biologics Stock News

Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer

Upgrades For iRobot Corp (NASDAQ:IRBT), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform. In the fourth quarter, iRobot showed an EPS of $1.05, compared to $0.84

Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat”

Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat”

The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc''s (NASDAQ: HCWB ) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. HCW9218 is an injectable, bifunctional fusion protein complex Full story available on Benzinga.com

The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tum

Aptorum APM +35%. HCW Biologics (HCWB) +18%. Star Equity STRR -30%. G Medical Innovations GMVD -21%.

HCW Biologics Inc (NASDAQ: HCWB ) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated that HCW9218 enhanced the anti-tumor efficacy of chemotherapy drugs and diminished their harmful side effects by reducing therapy-induced Full story available on Benzinga.com

HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated

A Novel Platform to Create Multi-Functional Immunotherapeutics for Cancer Will Feature TOBI™ Discovery Platform and Lead Product Candidate, HCW9218 A Novel Platform to Create Multi-Functional Immuno

MIRAMAR, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCW Biologics" or the "Company") (NASDAQ: HCWB ), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will speak at the Cambridge Healthtech Institute''s 24 th Annual PepTalk Conference to be held on January 17-19, 2022 ( https://www.chi-peptalk.com/protein-expression-production ). The conference is taking place virtually and in person at the Hilton San Diego Bayfront in San Diego, California. Dr. Wong''s presentation entitled, "A Novel Platform to Create Multi-Functional Immunotherapeutics for Cancer," is part of the session for Recombinant Protein Expression and Production: Effective Expression and Production of Unique Bioproducts and takes place on January 19 at 11:15 a.m. PST. His presentation will feature a discussion of the Company''s internally developed platform for drug discovery called the TOBI (Tissue factOr-Based fusIon) platform.

MIRAMAR, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to len

MIRAMAR, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ: HCWB ), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, announced today that members of the HCW Biologics management team will participate in the H.C. Wainwright BioConnect Conference. The event is taking place January 10 13, 2022. The Company will provide a corporate overview, including an update on its pipeline and the company''s plans to initiate multiple clinical trials for cancer in the first half of 2022. Presenters will include: Hing C. Wong, Ph.D., Founder and CEO; Peter Rhode, Ph.D., CSO and VP of Clinical Operations; Rebecca Byam, CFO; and Nicole Valdivieso, Director of Legal Affairs. The presentation will be available on the HCW Biologics investor relations website beginning on Monday, January 10, 2022. About HCW Biologics: HCW Biologics is a transformative immunotherapy company that focuses on inflammaging, a state of unresolved inflammatory responses and chronic inflammation.

Award recognizes extraordinary contributions to the growth of life sciences Award recognizes extraordinary contributions to the growth of life sciences

HCW Biologics Inc (NASDAQ:HCWB) was the recipient of a large growth in short interest in October. As of October 29th, there was short interest totalling 155,400 shares, a growth of 60.0% from the October 14th total of 97,100 shares. Approximately 1.3% of the companys shares are short sold. Based on an average daily volume of []